Recruiting
Phase 2

Biocidin REMOVE

Sponsor:

Johns Hopkins University

Code:

NCT07768267

Conditions

Irritable Bowel Syndrome (IBS)

Small Intestinal Bacterial Overgrowth Syndrome (SIBO)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biocidin REMOVE

Placebo

Study Details

Brief summary:

The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal bacterial overgrowth (SIBO) in adults with irritable bowel syndrome (IBS). SIBO means there are too many bacteria in the small intestine. It can make IBS symptoms worse.

This is a small first study, called a pilot study. Its results will help researchers plan larger studies.

The main questions it aims to answer are:

Does Biocidin REMOVE clear SIBO? Does it lower IBS symptoms and improve quality of life? Does it change the mix of bacteria in the gut? Researchers will compare Biocidin REMOVE to a placebo. A placebo is a look-alike capsule that contains no active ingredients. Neither the participants nor the research team will know who gets which one. About 40 adults age 18 and older will take part.

Participants will:

Take capsules by mouth twice a day for about 5 weeks. Participants will start with a low dose and build up to 2 capsules twice a day.

Take a breath test at the start and at the end of treatment. This test checks for SIBO.

Collect a stool sample at home at the start and at the end of treatment. Answer questions about symptoms and quality of life. Report what was eaten during the study. Come back for one check-in about 4 weeks after treatment ends.

Conditions

Irritable Bowel Syndrome (IBS)

Small Intestinal Bacterial Overgrowth Syndrome (SIBO)

Study ID

NCT07768267

Start date

Oct 26, 2026

Status verified date

Nov, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 18 years or older
  • Irritable bowel syndrome by Rome IV criteria with a positive lactulose breath test for small intestinal bacterial overgrowth, defined as a rise of more than 20 parts per million of hydrogen above baseline in the first 90 minutes of testing and/or a methane level of 10 parts per million or greater at any point during the test

OR

  • Irritable bowel syndrome by Rome IV criteria with a lactulose breath test showing a "flat line pattern," with exhaled gas levels remaining very low (3 parts per million or less) with no spikes
  • Female participants of childbearing age who are sexually active with male partners must agree to use a highly effective method of contraception, such as abstinence, hormonal contraceptive, intrauterine device, or bilateral tubal occlusion

Exclusion Criteria:

  • Negative SIBO breath testing at baseline
  • Restricted diets (low carbohydrate, Atkins, gluten-free, low FODMAP, or others)
  • Confirmed celiac disease
  • Immunocompromised (chronic steroids, biologics), CD4 less than 400, AIDS not on therapy, neutropenia, acute and chronic leukemia, lymphoma
  • Portal hypertension
  • Chronic liver disease, defined as: ICD-10 known diagnoses of chronic liver disease; OR known or suspected liver cirrhosis, portal hypertension, or chronic hepatitis; OR serum AST and ALT elevation greater than 2 times the upper limit of normal with decreased serum albumin less than 4.0 g/dL within the last 6 months
  • Pregnant or breastfeeding
  • Diagnosis of inflammatory bowel disease
  • Poorly controlled anxiety or depression despite medication
  • Untreated significant anxiety or depression
  • COVID-19 positive
  • Unable to provide informed consent
  • Insulin dependent or poorly controlled diabetes mellitus (HbA1c greater than 7.0%)
  • Connective tissue disease such as lupus or scleroderma
  • Concurrent narcotic use
  • Antibiotic or probiotic use within 30 days

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Biocidin REMOVE

Participants receive Biocidin REMOVE capsules, a herbal preparation supplied as a 665 mg capsule containing 325 mg of the active proprietary blend. Dosing begins with a 9-day titration, increasing by one capsule every three days: one capsule once daily on Days -9 to -7, one capsule twice daily on Days -6 to -4, and two capsules in the morning with one in the evening on Days -3 to -1. Participants reach the target dose of two capsules twice daily on Day 1 and continue at that dose through Day 28. Capsules are identical in appearance to placebo.

placebo comparator: Placebo

Participants receive matching placebo capsules, identical in appearance to Biocidin REMOVE and containing no active ingredients. Placebo follows the same 9-day titration and dosing schedule as the experimental arm: one capsule once daily on Days -9 to -7, one capsule twice daily on Days -6 to -4, two capsules in the morning with one in the evening on Days -3 to -1, then two capsules twice daily on Days 1 through 28.

Interventions

Biocidin REMOVE

Herbal preparation supplied as a 665 mg capsule containing 325 mg of an active proprietary blend, taken by mouth. Participants titrate over 9 days, increasing by 1 capsule every 3 days, to a target dose of 2 capsules twice daily. The target dose is maintained from Day 1 through Day 28. Capsules are identical in appearance to a placebo and are dispensed by the Johns Hopkins Hospital Investigational Drug Service.

Manufacturer Information - https://biocidin.com/products/biocidin-liquid-capsules?srsltid=AYCX9vIz70t1GitW7aRKw54Cxydhf0-Gi1e8HUUVVsP7tuSi7X6yscSC

Placebo

Matching placebo capsules, identical in appearance to Biocidin REMOVE and containing no active ingredients, taken by mouth on the same schedule: a 9-day titration increasing by one capsule every three days, reaching two capsules twice daily from Day 1 through Day 28.

Primary outcome measure

  • Proportion of Participants With Remission of Small Intestinal Bacterial Overgrowth [ Time Frame: Day 28 ]

Central Contacts and Locations

Locations

Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Principal Investigator:

Gerard Mullin, MD

More Information

Sponsor

Johns Hopkins University

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • SIBO
  • IBS
  • Herbal supplement
  • Antimicrobial herbal therapy
  • Gut microbiome
  • Dysbiosis
  • Rome IV
  • Hydrogen breath test
  • Lactulose breath test

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Johns Hopkins University on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.